Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innoviva Inc INVA

Healthcare Biotechnology
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA... see more

Recent & Breaking News (NDAQ:INVA)

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

PR Newswire March 12, 2025

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Business Wire March 5, 2025

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Business Wire February 26, 2025

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire February 6, 2025

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Business Wire December 16, 2024

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Business Wire November 26, 2024

Innoviva to Participate in the UBS Global Healthcare Conference

Business Wire November 12, 2024

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire November 6, 2024

Innoviva to Participate in Upcoming Investor Conferences

Business Wire September 4, 2024

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire July 31, 2024

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 3, 2024

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire May 8, 2024

Innoviva to Participate in the BofA Securities Health Care Conference

Business Wire May 8, 2024

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Business Wire April 24, 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

PR Newswire March 4, 2024

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Business Wire February 29, 2024

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Business Wire November 1, 2023

Innoviva to Participate in the Cantor Global Healthcare Conference

Business Wire September 19, 2023

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Business Wire September 18, 2023

Innoviva Appoints Stephen Basso as Chief Financial Officer

Business Wire August 25, 2023